Idiopathic thrombocytopenic purpura in pregnancy and neonatal period.
In pregnancy and neonatal period both mother and child are endangered by bleeding complications due to maternal idiopathic thrombocytopenic purpura. Obstetrical and perinatal management therefore must aim at increasing maternal and fetal platelet count. In our paper six patients in nine pregnancies are reported. Two of them (five pregnancies) were treated with corticosteroids, four of the patients were successfully treated with i.v. immunoglobulins (IgG). Longterm steroid application and splenectomy during pregnancy may be hazardous for mother and fetus. IgG i.v. administration in contrast offers a new and safe way to control maternal and fetal platelet counts during pregnancy, delivery and the neonatal period.
D000328:Adult; D001803:Blood Transfusion; D002585:Cesarean Section; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007231:Infant, Newborn; D010976:Platelet Count; D017713:Platelet Transfusion; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000503:physiopathology*; D011696:Purpura, Thrombocytopenic / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D013156:Splenectomy
D007074:Immunoglobulin G; D011241:Prednisone